Cargando…

A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS)

Irritable bowel syndrome (IBS) remains a prevalent and difficult-to-manage gastrointestinal condition. There is growing interest in the use of traditional medicine to manage IBS. In particular, curcumin, a biologically active phytochemical, has demonstrated anti-inflammatory and anti-oxidant propert...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Qin Xiang, Soh, Alex Yu Sen, Loke, Wayren, Venkatanarayanan, Nandini, Lim, Donovan Yutong, Yeo, Wee-Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210149/
https://www.ncbi.nlm.nih.gov/pubmed/30248988
http://dx.doi.org/10.3390/jcm7100298
_version_ 1783367047876444160
author Ng, Qin Xiang
Soh, Alex Yu Sen
Loke, Wayren
Venkatanarayanan, Nandini
Lim, Donovan Yutong
Yeo, Wee-Song
author_facet Ng, Qin Xiang
Soh, Alex Yu Sen
Loke, Wayren
Venkatanarayanan, Nandini
Lim, Donovan Yutong
Yeo, Wee-Song
author_sort Ng, Qin Xiang
collection PubMed
description Irritable bowel syndrome (IBS) remains a prevalent and difficult-to-manage gastrointestinal condition. There is growing interest in the use of traditional medicine to manage IBS. In particular, curcumin, a biologically active phytochemical, has demonstrated anti-inflammatory and anti-oxidant properties and mucosal protective effects in rat models of colitis. This meta-analysis thus aimed to investigate the hypothesis that curcumin improves IBS symptoms. Using the keywords (curcumin OR turmeric OR Indian saffron OR diferuloylmethane OR curcuminoid) AND (irritable bowel syndrome OR IBS), a preliminary search on the PubMed, Medline, Embase, PsychINFO, Web of Science, and Google Scholar databases yielded 1080 papers published in English between 1 January 1988 and 1 May 2018. Five randomized, controlled trials were systematically reviewed and 3 were included in the final meta-analysis. Random-effects meta-analysis based on three studies and 326 patients found curcumin to have a beneficial albeit not statistically significant effect on IBS symptoms (pooled standardized mean difference from baseline IBS severity rating −0.466, 95% CI: −1.113 to 0.182, p = 0.158). This is the first meta-analysis to examine the use of curcumin in IBS. With its unique anti-oxidant and anti-inflammatory activities and ability to modulate gut microbiota, curcumin is a potentially useful addition to our armamentarium of agents for IBS. It also appears safe and well-tolerated, with no adverse events reported in the available trials. However, current findings are based on a considerably limited evidence base with marked heterogeneity. More robust clinical trials involving a standardized curcumin preparation and larger sample sizes should be encouraged.
format Online
Article
Text
id pubmed-6210149
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62101492018-11-02 A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS) Ng, Qin Xiang Soh, Alex Yu Sen Loke, Wayren Venkatanarayanan, Nandini Lim, Donovan Yutong Yeo, Wee-Song J Clin Med Article Irritable bowel syndrome (IBS) remains a prevalent and difficult-to-manage gastrointestinal condition. There is growing interest in the use of traditional medicine to manage IBS. In particular, curcumin, a biologically active phytochemical, has demonstrated anti-inflammatory and anti-oxidant properties and mucosal protective effects in rat models of colitis. This meta-analysis thus aimed to investigate the hypothesis that curcumin improves IBS symptoms. Using the keywords (curcumin OR turmeric OR Indian saffron OR diferuloylmethane OR curcuminoid) AND (irritable bowel syndrome OR IBS), a preliminary search on the PubMed, Medline, Embase, PsychINFO, Web of Science, and Google Scholar databases yielded 1080 papers published in English between 1 January 1988 and 1 May 2018. Five randomized, controlled trials were systematically reviewed and 3 were included in the final meta-analysis. Random-effects meta-analysis based on three studies and 326 patients found curcumin to have a beneficial albeit not statistically significant effect on IBS symptoms (pooled standardized mean difference from baseline IBS severity rating −0.466, 95% CI: −1.113 to 0.182, p = 0.158). This is the first meta-analysis to examine the use of curcumin in IBS. With its unique anti-oxidant and anti-inflammatory activities and ability to modulate gut microbiota, curcumin is a potentially useful addition to our armamentarium of agents for IBS. It also appears safe and well-tolerated, with no adverse events reported in the available trials. However, current findings are based on a considerably limited evidence base with marked heterogeneity. More robust clinical trials involving a standardized curcumin preparation and larger sample sizes should be encouraged. MDPI 2018-09-22 /pmc/articles/PMC6210149/ /pubmed/30248988 http://dx.doi.org/10.3390/jcm7100298 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ng, Qin Xiang
Soh, Alex Yu Sen
Loke, Wayren
Venkatanarayanan, Nandini
Lim, Donovan Yutong
Yeo, Wee-Song
A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS)
title A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS)
title_full A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS)
title_fullStr A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS)
title_full_unstemmed A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS)
title_short A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS)
title_sort meta-analysis of the clinical use of curcumin for irritable bowel syndrome (ibs)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210149/
https://www.ncbi.nlm.nih.gov/pubmed/30248988
http://dx.doi.org/10.3390/jcm7100298
work_keys_str_mv AT ngqinxiang ametaanalysisoftheclinicaluseofcurcuminforirritablebowelsyndromeibs
AT sohalexyusen ametaanalysisoftheclinicaluseofcurcuminforirritablebowelsyndromeibs
AT lokewayren ametaanalysisoftheclinicaluseofcurcuminforirritablebowelsyndromeibs
AT venkatanarayanannandini ametaanalysisoftheclinicaluseofcurcuminforirritablebowelsyndromeibs
AT limdonovanyutong ametaanalysisoftheclinicaluseofcurcuminforirritablebowelsyndromeibs
AT yeoweesong ametaanalysisoftheclinicaluseofcurcuminforirritablebowelsyndromeibs
AT ngqinxiang metaanalysisoftheclinicaluseofcurcuminforirritablebowelsyndromeibs
AT sohalexyusen metaanalysisoftheclinicaluseofcurcuminforirritablebowelsyndromeibs
AT lokewayren metaanalysisoftheclinicaluseofcurcuminforirritablebowelsyndromeibs
AT venkatanarayanannandini metaanalysisoftheclinicaluseofcurcuminforirritablebowelsyndromeibs
AT limdonovanyutong metaanalysisoftheclinicaluseofcurcuminforirritablebowelsyndromeibs
AT yeoweesong metaanalysisoftheclinicaluseofcurcuminforirritablebowelsyndromeibs